Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Dr Kelly on Early Efficacy Signals and Safety With Sacituzumab Govitecan in Recurrent Glioblastoma

April 7th 2025

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

VXM01 Plus Avelumab Is Safe and Shows Preliminary Clinical Activity in Recurrent Glioblastoma

April 7th 2025

The combination of VXM01 and avelumab was well tolerated and has the potential to generate clinically meaningful responses in recurrent glioblastoma.

FDA Gives RPDD to NEO100 for Pediatric-Type Diffuse High-Grade Glioma

April 3rd 2025

NEO100 was given rare pediatric disease designation by the FDA for the treatment of patients with pediatric-type diffuse high-grade glioma.

Dr Ayoub on an AI Model to Enhance Interpretability of Morphologic Heterogeneity in Glioblastoma

March 28th 2025

Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.

Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG

March 24th 2025

A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

FDA Grants Priority Review to Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

February 18th 2025

The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.

Dr McNall-Knapp on HRQOL Outcomes With Mirdametinib in NF1-PN

February 10th 2025

Rene Y. McNall-Knapp, MD, discusses HRQOL outcomes from the ReNeu trial investigating mirdametinib in patients with NF1-PN.

Dr Colman on Outcomes With Eflornithine in Grade 3 Anaplastic Astrocytoma

February 10th 2025

Howard Colman, MD, PhD, discusses the STELLAR trial of eflornithine plus lomustine vs lomustine alone in recurrent, IDH-mutant, anaplastic astrocytoma.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

A Nuanced Understanding of Cellular Biology Advances Neuro-Oncology Practice: With D. Ross Camidge, MD, PhD; and Adrienne A. Boire, MD, PhD

January 22nd 2025

Drs Camidge and Boire discuss Dr Boire's path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.

FDA Approves Companion Diagnostic for Tovorafenib in BRAF-Altered Pediatric Low-Grade Glioma

January 17th 2025

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma

January 7th 2025

A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.

FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

January 2nd 2025

A NDA has been submitted to the FDA seeking the approval of dordaviprone for recurrent H3K27M-mutant diffuse glioma.

Dr Baker on the EMBRACE Trial of the Dxcover Liquid Biopsy in Brain Cancer

December 19th 2024

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.

Dr Ahluwalia on the SURVIVE Trial of SurVaxM Plus Chemoradiation in Newly-Diagnosed Glioblastoma

December 19th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

Belzutifan Earns Positive CHMP Opinion for VHL Disease–Associated Tumors, Advanced ccRCC

December 13th 2024

The EMA’s CHMP has recommended the approval of belzutifan monotherapy for patients with select VHL disease–associated cancers.

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

December 2nd 2024

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma

November 25th 2024

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

November 25th 2024

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.